NFKB1 and neoplasm: Targeting the NF-κB pathway has been of clinical interest for many years given its established role in driving tumour progression; however, so far, attempts to generate targeted NF-κB inhibitors for clinical use have failed, largely due to toxicity issues as a result of the multifaceted roles of the numerous NF-κB subunits in normal physiology [16].